TTR and juvenile Huntington disease: Investigational ASOs for Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and transthyretin (TTR) amyloidosis, such as RG6042, tofersen and inotersen, respectively, are currently in phase III clinical trials.